Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Metsera Reports Up To 14% Weight Loss In Phase 2b Obesity Trial

Close-up,Of,Person,Standing,On,Digital,Bathroom,Scale,In,Cozy

Metsera, Inc. (NASDAQ:MTSR) on Tuesday released topline data from VESPER-1 and data from a planned interim analysis for tolerability of VESPER-3 – two Phase 2b trials of MET-097i with potential for monthly dosing.

In VESPER-1, MET-097i demonstrated a mean placebo-subtracted weight loss of up to 14.1% after 28 weekly doses.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.